ArticleOncotarget2026
Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer.
Article in Oncotarget, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Copyright: © 2026 Duval et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Collagen triple helix repeat containing 1 (CTHRC1) is a secreted protein that has previously been explored for its role in tissue remodeling and cancer. However, its function in the tumor microenvironment (TME) remains poorly understood, despite its known expression in tumor-associated stroma. Colorectal cancer (CRC), a malignancy characterized by extensive stromal involvement, poses an excellent opportunity to investigate this gap. Here, we provide the first evidence that host-derived CTHRC1 drives colon cancer progression, with this effect consistently observed across three independent cohorts. Specifically, when injected with CRC cells, Cthrc1 null (global knockout, KO) mice develop significantly smaller and less dense tumors compared to wild-type (WT) mice. Additionally, median survival increased approximately 2.5-fold in Cthrc1 KO mice, from 28 days post-inoculation in WT (n = 10) to 69 days in CTHRC1-deficient mice (n = 10), suggesting CTHRC1 promotes tumor growth within the TME. Immune cell profiling revealed differences in the composition of tumors and spleens of these mice; specifically, Cthrc1 KO mice exhibited an increased percentage of CD3+ T cells in both tumors and spleens and decreased Gr-1+ myeloid cells in the spleen, compared to WT, indicating an immunoregulatory role for CTHRC1 in CRC. These results identify CTHRC1 as a key driver of CRC that may suppress the immune system, allowing for easier immune evasion by tumor cells, highlighting CTHRC1 as a potential new target for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.